Stabilised vaccine composition
AssigneeGlaxosmithkline Biologicals SA
InventorsDominique Ingrid LEMOINE, Sophie Valerie Anne Ponsard
Life of this patent
Estimating the term…
Abstract
A component for a HIV vaccine comprising: a) an immunogenic fusion protein comprising Nef or an immunogenic fragment or derivative thereof, and p17 Gag and/or p24 Gag or immunogenic fragments or derivatives thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them, and b) a stabilising agent selected from the group comprising or consisting of monothioglycerol, cysteine, N-acetyl cysteine or mixtures thereof. The invention also extends to HIV vaccines comprising the same and use in treatment/prevention of HIV.
Claims31
An immunogenic composition comprising:
- a) an immunogenic fusion protein a Nef polypeptide or immunogenic fragment thereof, a Gag polypeptide or immunogenic fragment thereof, and a reverse transcriptase (RT) polypeptide or immunogenic fragment thereof, and
- b) an antioxidant selected from the group consisting of monothioglycerol, cysteine, N-acetyl cysteine or mixtures thereof.
An immunogenic composition comprising:
- a) an immunogenic fusion protein comprising a Nef polypeptide or immunogenic fragment thereof, a Gag polypeptide or immunogenic fragment thereof, and a reverse transcriptase (RT) polypeptide or immunogenic fragment thereof,
- b) a stabilising agent which is an antioxidant selected from the group consisting of monothioglycerol, cysteine, N-acetyl cysteine and mixtures thereof,
- c) 1% w/v or less of a non-ionic surfactant,
- d) 200 to 450 mM of arginine,
- e) 0.5 to 2.0 mM of a chelating agent, and
- f) 1 to 50 mM of a buffer.
Dependencies are inferred from the claim text.